نتایج جستجو برای: pediatric aml and prognosis
تعداد نتایج: 16873517 فیلتر نتایج به سال:
Background: Blood cancer (leukemia) is the cancer of blood tissue and Acute Myeloid Leukemia (AML) is the third most prevalent type in Iran. Survival time after diagnosis and its risk factors are one of the most important indicators for assessing the treatment. Methods: Data for this prospective study belong to Valiasr 2 (Imam Khomeini Hospital) AML patients during 2008-2013. A total of 85 p...
Pediatric de novo acute myeloid leukemia (AML) is an aggressive malignancy with current therapy resulting in cure rates of only 60%. To better understand the cause of the marked heterogeneity in therapeutic response and to identify new prognostic markers and therapeutic targets a comprehensive list of the genetic mutations that underlie the pathogenesis of AML is needed. To approach this goal, ...
Althoughmost children with acute myeloid leukemia (AML) achieve complete remission, the relapse rate is 30% to 40%. Because it is thought that leukemia-initiating cells (LIC) are responsible for AML relapses, targeting these cells might improve outcome. Treatment of pediatric AML blasts with the receptor tyrosine kinase (RTK) inhibitor PTK787/ZK222584 (PTK/ZK) induces cell death in vitro.Howeve...
Although most children with acute myeloid leukemia (AML) achieve complete remission, the relapse rate is 30% to 40%. Because it is thought that leukemia-initiating cells (LIC) are responsible for AML relapses, targeting these cells might improve outcome. Treatment of pediatric AML blasts with the receptor tyrosine kinase (RTK) inhibitor PTK787/ZK 222584 (PTK/ZK) induces cell death in vitro. How...
acute myeloid leukemia (aml) is a type of poor prognosis hematological malignancies characterized by heterogeneous clonal expansion of myeloid progenitors. leukemic stem cells are thought to form the majority of a cell population in minimal residual diseases (mrds) which are resistant to current chemotherapeutic regimens and mediate disease relapse. current therapeutic vaccine strategies have d...
BACKGROUND AND OBJECTIVES Cytogenetics is the most important prognostic factor in acute myeloid leukemia (AML). However, a high proportion of patients show normal or intermediate-risk karyotypes. In these patients, other determinants could help to identify those with a higher risk of relapse. Recently, internal tandem duplications (ITD) and D835 mutations in FLT3 tyrosine kinase receptor have b...
Recently it was shown that, analogous to normal hematopoietic cells, the level of CXC chemokine receptor 4 (CXCR-4) expression on acute myeloid leukemia (AML) cells correlates with stromal cell derived factor-1 alpha (SDF-1)-induced chemotaxis. As we speculated that an anomalous organ distribution of AML cells could affect cell survival and thus result in an altered fraction surviving chemother...
Acute myeloid leukemia (AML) accounts for approximately 15-20% of all childhood leukemias, and despite dramatic improvements in treatment outcome, only approximately 70% of children with AML are cured. AML results from collaborating genetic aberrations in at least 2 different classes; type-I aberrations, inducing uncontrolled cell proliferation and/or survival, and type-II aberrations inhibitin...
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is a heterogeneous malignancy characterized by distinct genetic and epigenetic abnormalities. Recent genome-wide DNA methylation studies have highlighted an important role of dysregulated methylation signature in AML from biological and clinical standpoint. In this review, we will outline the recent advances i...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید